A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males
Status:
Completed
Trial end date:
2018-05-22
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability and efficacy of the oral administration of
setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males
with androgenetic alopecia (AGA).